Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thomas S. Uldrick"'
Autor:
Suzanne George, Caroline Schenkel, S. Percy Ivy, Edward S. Kim, Gwynn Ison, Mark Stewart, Patricia A. Spears, Diana Merino Vega, Richard L. Schilsky, Thomas S. Uldrick, Alexander I. Spira, James L. Wade, Andrea Denicoff, Allison Magnuson, Raymond P. Perez, Suanna S. Bruinooge, R. Donald Harvey, Julia A. Beaver, William D. Tap
Publikováno v:
Clinical Cancer Research. 27:2394-2399
Purpose: Restrictive clinical trial eligibility criteria (EC) limit the number of patients who can enroll and potentially benefit from protocol-driven, investigational treatment plans and reduce the generalizability of trial results to the broader po
Autor:
Kathryn Finch Mileham, Cassadie Moravek, Andrew S. Kennedy, Thomas S. Uldrick, E. Claire Dees, Caroline Schenkel, Scot Ebbinghaus, S. Percy Ivy, Jamie Renee Brewer, Atiqur Rahman, R. Donald Harvey, Vishal Bhatnagar, Elizabeth Ness
Publikováno v:
Clin Cancer Res
Purpose: Washout periods and concomitant medication exclusions are common in cancer clinical trial protocols. These exclusion criteria are often applied inconsistently and without evidence to justify their use. The authors sought to determine how was
Publikováno v:
Curr HIV/AIDS Rep
PURPOSE OF REVIEW: Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) pathway are a class of anti-cancer immunotherapy agents changing treatment paradigms of many cancers that occur at higher rates in people living with HIV (PL
Autor:
Jeff Allen, Pratik S. Multani, Edward S. Kim, Rajeshwari Sridhara, Tatiana M. Prowell, Nancy Roach, Gwynn Ison, Elizabeth Garrett-Mayer, Suanna S. Bruinooge, Thomas S. Uldrick, Stuart M. Lichtman, Marina Kozak, Ellen V. Sigal, Lia Gore, Samantha A. Roberts, Paul J. Hesketh, Richard L. Schilsky, Caroline Schenkel, Nan Lin, Julia A. Beaver, Andrea M. Denicoff, Eric J. Rubin
Publikováno v:
Journal of Clinical Oncology. 35:3737-3744
Purpose The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardize the generalizability of resu